TrialThe Lancet. Oncology2011

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Hervé Bonnefoi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.